Nebenwirkungen · Bimzelx
Bimzelx 160 mg solution for injection in pre-filled syringe Bimzelx 320 mg solution for injection in pre-filled syringe Bimzelx 160 mg solution for injection in pre-filled pen Bimzelx 320 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 8
HOS-146294 · Präparat HOS-099486
Approximately 45% of plaque psoriasis patients treated with bimekizumab up to 56 weeks at the recommended dosing regimen (320 mg every 4 weeks up to week 16 and 320 mg every 8 weeks thereafter) developed anti-drug antibodies. Of the patients who developed anti-drug antibodies, approximately 34% (16% of all patients treated with bimekizumab) had antibodies that were classified as neutralising.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T16:53:00Z · SHA-256 caa921571142f6a5edc79dd18f7931333acd6330de2f856395887db3b9d20aca · Passage 1aa6e1cc7cef26425a6f9c453e3c6a21483ba6edbe38fcb144b25fabc877a98f · Zeichen 5754–6149 im Abschnitt